<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311244</url>
  </required_header>
  <id_info>
    <org_study_id>URomLS-01-2014</org_study_id>
    <nct_id>NCT02311244</nct_id>
  </id_info>
  <brief_title>The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes</brief_title>
  <acronym>SUMMER</acronym>
  <official_title>The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes: Identification of New Molecular Promoters of Mortality and Morbidity in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Sandro Pertini, Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Camillo Forlanini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cagliari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Casa Sollievo della Sofferenza IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study is aimed at identifying new molecular promoters of mortality (and
      morbidity) in patients with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Mortality rate of diabetic patients is about twice as much that of non-diabetic
      individuals of similar age; this makes diabetes a leading risk factor for mortality,
      especially of cardiovascular origin, which accounts for 2.9 million global events yearly.
      Such scenario is expected to further deteriorate, given that the prevalence of type 2
      diabetes mellitus (T2DM), by far the most common form of diabetes comprising more than 90% of
      all diabetic individuals, is increasing worldwide. Predicting such devastating event is,
      therefore, urgently needed in order to target aggressive prevention strategies in high risk
      T2DM patients.

      Aims This observational study is aimed at identifying new molecular promoters of all-cause
      mortality in patients with T2DM.

      Secondary endpoints are to identify in these individuals molecular markers of

        -  cardiovascular mortality;

        -  myocardial infarction;

        -  stroke;

        -  dialysis.

      Other pre-specified endpoints are to assess in these subjects:

        -  LADA;

        -  severe hypoglycemic episodes;

        -  revascularization procedures;

        -  hospitalization for heart failure;

        -  other co-morbidities (cancer - at follow-up only, liver disease, chronic obstructive
           pulmonary disease, autoimmune and endocrine disorders, other - non-diabetic - renal
           diseases, fractures, cognitive impairment).

      Patients A total of 5,000 patients with T2DM of both sexes will be recruited. Measures The
      following parameters will be recorded as exposure variables at baseline.

        -  Age, BMI, waist circumference, systolic and diastolic pressure;

        -  Lifestyle habits, including diet, physical activity (both by validated questionnaires)
           and smoking.

        -  Menopausal state (for women).

        -  Family history of diabetes (3 consecutive generations).

        -  Family history of cardiovascular disease (first degree relatives).

        -  Diabetes duration.

        -  Severe (requiring assistance) hypoglycemic episodes (per year).

        -  Myocardial infarction, stroke, ulcer/gangrene/amputation, coronary and peripheral
           revascularization, hospitalization for heart failure, dialysis (at follow-up only).

        -  Glucose, HbA1c, creatinine, uric acid, total and HDL cholesterol, triglycerides, high
           sensitive C reactive protein, testosterone, Vitamin D, uric acid levels, white blood
           cells counting, urinary albumin creatinine ratio (ACR)

        -  Current glucose-, lipid-, blood pressure-lowering and anti-platelet or anti-coagulant
           treatment.

        -  Other relevant treatments (steroids, NSAIDs, immunomodulators, androgens, estrogens,
           anti-fracturative therapy).

        -  Main co-morbidities (cancer, chronic liver disease, chronic obstructive pulmonary
           disease, autoimmune and endocrine disorders, other - non-diabetic - renal diseases,
           fractures, cognitive impairment).

      The following parameters will be assessed at baseline only:

        -  GADAs (by a radiobinding assay using in vitro translated [35S] methionine-labelled
           GAD65) and IA-2 antibodies (by radioimmunoprecipitation assays) to identify subjects
           with LADA.

        -  Genomic (common and rare variants in genes of interest according to a pathway-centric
           approach by means of Affymetrix platforms), transcriptomic (differential levels of mRNA
           by GeneChip Human Gene 1.0 ST Array from Affymetrix) and metabolomic by a combination of
           ultra-pressure liquid chromatography and gas chromatography coupled to mass
           spectrometry) analysis.

      Measurements of testosterone, Vitamin D, GADAs and IA-2 antibodies as well as gnomic,
      transcriptomic and metabolomic analysis will be centralized.

      Time schedule Recruitment of patients will last approximately 3 years. The enrolled patients
      will be followed for at least 5 years with yearly visits and telephone calls or consultation
      of death records in case of drop-out for unknown reasons.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of all-cause deaths</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants who die for all causes and time of occurrence of such events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cardiovascular deaths</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants who die for cardiovascular causes and time of occurrence of such events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with myocardial infarction</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants who develop myocardial infarction and time of occurrence of such events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with stroke</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants who develop stroke and time of occurrence of such events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects entering dialysis</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants who enter dialysis and time of occurrence of such events</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Secondary care outpatients clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 diabetes mellitus

        Exclusion Criteria:

          -  Severe psychiatric illnesses

          -  End-stage renal disease and dialysis

          -  Cirrhosis

          -  Any active cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Trischitta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Roma La Sapienza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Pugliese, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Roma La Sapienza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincenzo Trischitta, MD</last_name>
    <phone>+390644160534</phone>
    <email>vincenzo.trischitta@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Pugliese, MD, PhD</last_name>
    <phone>+390633775440</phone>
    <email>giuseppe.pugliese@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Roma La Sapienza</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Trischitta, MD</last_name>
      <phone>+390644160534</phone>
      <email>vincenzo.trischitta@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Pugliese, MD, PhD</last_name>
      <phone>+390633775440</phone>
      <email>giuseppe.pugliese@uniroma1.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.summerstudyindiabetes.it/</url>
    <description>Study webpage</description>
  </link>
  <reference>
    <citation>Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Nj√∏lstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011 Mar 3;364(9):829-841. doi: 10.1056/NEJMoa1008862. Erratum in: N Engl J Med. 2011 Mar 31;364(13):1281.</citation>
    <PMID>21366474</PMID>
  </reference>
  <reference>
    <citation>Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005 Sep;28(9):2130-5.</citation>
    <PMID>16123478</PMID>
  </reference>
  <reference>
    <citation>De Cosmo S, Copetti M, Lamacchia O, Fontana A, Massa M, Morini E, Pacilli A, Fariello S, Palena A, Rauseo A, Viti R, Di Paola R, Menzaghi C, Cignarelli M, Pellegrini F, Trischitta V. Development and validation of a predicting model of all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2013 Sep;36(9):2830-5. doi: 10.2337/dc12-1906. Epub 2013 May 1.</citation>
    <PMID>23637348</PMID>
  </reference>
  <reference>
    <citation>Hong Kong Diabetes Registry, Yang X, So WY, Tong PC, Ma RC, Kong AP, Lam CW, Ho CS, Cockram CS, Ko GT, Chow CC, Wong VC, Chan JC. Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med. 2008 Mar 10;168(5):451-7. doi: 10.1001/archinte.168.5.451.</citation>
    <PMID>18332288</PMID>
  </reference>
  <reference>
    <citation>Wells BJ, Jain A, Arrigain S, Yu C, Rosenkrans WA Jr, Kattan MW. Predicting 6-year mortality risk in patients with type 2 diabetes. Diabetes Care. 2008 Dec;31(12):2301-6. doi: 10.2337/dc08-1047. Epub 2008 Sep 22.</citation>
    <PMID>18809629</PMID>
  </reference>
  <reference>
    <citation>McEwen LN, Karter AJ, Waitzfelder BE, Crosson JC, Marrero DG, Mangione CM, Herman WH. Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care. 2012 Jun;35(6):1301-9. doi: 10.2337/dc11-2281. Epub 2012 Mar 19.</citation>
    <PMID>22432119</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Vincenzo Trischitta</investigator_full_name>
    <investigator_title>MD, Professor of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>All-cause mortality</keyword>
  <keyword>Cardiovascular mortality</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Stroke</keyword>
  <keyword>Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

